Compass Therapeutics to Present at Upcoming Investment Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BOSTON, Nov. 08, 2022 - Compass Therapeutics, Inc. (Nasdaq: CMPX) announced its participation in two key investor conferences this November. The Stifel Healthcare Conference in New York City is scheduled for November 15, 2022, from 4:10-4:40 PM ET. The Jefferies Global Healthcare Conference in London will take place on November 16, 2022, from 3:15-3:45 PM GMT. Both presentations will be available via webcast, with a replay accessible for 90 days. Compass Therapeutics focuses on developing antibody-based therapies targeting cancer.
Details
News Market Reaction – CMPX
The recorded move for CMPX in the trading session of this news was +10.10%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced it will be presenting at the following investor conferences during the month of November 2022.
Presentation details are as follows:
Stifel Healthcare Conference in New York City
Date: Tuesday, November 15, 2022
Time: 4:10-4:40 PM ET
Webcast Link: https://wsw.com/webcast/stifel74/cmpx/2109872
Jefferies Global Healthcare Conference in London, UK
Date: Wednesday, November 16, 2022
Time: 3:15 – 3:45 PM GMT
Webcast Link: https://wsw.com/webcast/jeff255/cmpx/1866024
Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
Mario Corso, Executive Director and Head of Investor Relations
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Communications Manager
media@compasstherapeutics.com
617-500-8099
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.